Introduction

Artificial intelligence (AI) is changing how pharmaceutical companies manage data, automate processes, analyse information, and support critical business decisions. However, introducing AI into regulated computerized systems also creates new challenges for Computerized System Validation (CSV) and GxP compliance.

Traditional CSV approaches focus on demonstrating that computerized systems consistently perform their intended functions. AI-based systems can behave differently because their outputs may depend on training data, model design, changing inputs, and algorithmic behaviour. As a result, pharmaceutical companies must carefully evaluate how these systems are validated, monitored, and maintained throughout their lifecycle.

Understanding AI and CSV validation challenges is essential for protecting data integrity, maintaining product quality, and supporting regulatory compliance. Companies must also establish appropriate documentation, risk management, change control, and human oversight procedures.

In this guide, GxP Cellators explains five major AI validation challenges and practical approaches for addressing them in pharmaceutical and other regulated life sciences environments.

What Is the Relationship Between AI and Computerized System Validation?

Computerized System Validation is a documented process used to demonstrate that a computerized system is suitable for its intended use. In pharmaceutical environments, validation helps ensure that systems operate reliably and protect product quality, patient safety, and data integrity.

AI can be integrated into various regulated activities, including quality control, manufacturing, laboratory analysis, pharmacovigilance, document review, and quality management systems.

For example, an AI-powered system might analyse laboratory results, identify unusual manufacturing patterns, or assist with reviewing quality records. If its output influences a GxP decision, the company must evaluate the system’s intended use and potential impact on regulated activities.

AI validation therefore requires more than testing conventional software functions. Organizations must also assess model performance, data quality, output variability, explainability, and the controls used to manage changes.

Challenge 1: Non-Deterministic AI Outputs

One of the major AI and CSV validation challenges is non-deterministic behaviour. Some AI systems may generate different outputs when given the same input, depending on model configuration, sampling methods, contextual information, or other technical factors.

For example, an AI tool used to summarize deviation reports might produce slightly different summaries for repeated requests. In a regulated environment, the company must determine whether those variations could affect the accuracy or reliability of the final decision.

How to Address Non-Deterministic Outputs

1. Define clear acceptance criteria

Organizations should establish measurable acceptance criteria based on the system’s intended use. These criteria should identify acceptable output variations and define which errors could affect product quality, patient safety, or data integrity.

2. Test the system across multiple runs

Testing should include repeated executions, representative inputs, boundary conditions, and challenging scenarios. This helps organizations understand how consistently the model performs under defined conditions.

3. Establish human review controls

Where AI outputs influence important GxP decisions, qualified personnel should review the results according to documented procedures. The level of review should reflect the associated risk.

4. Implement ongoing performance monitoring

Monitoring helps identify unexpected changes in output quality, accuracy, or consistency. Companies should document deviations from expected performance and investigate significant issues.

Challenge 2: Continuous Learning and Model Changes

Some AI systems can be updated or retrained using new data. Even when a model does not learn automatically during operation, developers may periodically release updated versions.

These changes can affect how the system processes information and produces results. Consequently, a model that performed acceptably during initial validation might behave differently after an update.

Uncontrolled changes can create compliance risks, particularly when the system supports manufacturing decisions, laboratory operations, quality investigations, or other GxP activities.

How to Manage Continuous Learning

1. Establish formal change control

Every relevant model update, configuration change, or modification to training data should be assessed through an appropriate change control process. The assessment should document the reason for the change and its potential impact.

2. Define revalidation triggers

Organizations should establish criteria for determining when additional testing or revalidation is necessary. Triggers may include significant changes to the model, intended use, underlying data, or risk profile.

3. Maintain model version records

Companies should document model versions, approval status, relevant configurations, and the associated validation evidence. This makes it easier to establish which version was used when a particular result was generated.

4. Monitor performance after changes

Following an approved update, organizations should verify that the system continues to meet its intended requirements. Monitoring should include relevant performance indicators and documented procedures for investigating unexpected results.

Challenge 3: Lack of Transparency and Explainability

Some AI models are difficult to interpret because their outputs result from complex relationships within the model. This can make it challenging for pharmaceutical companies to understand why a particular recommendation or prediction was generated.

For regulated organizations, unexplained outputs may create difficulties during internal audits, regulatory inspections, and quality investigations. Companies need sufficient information to evaluate whether an AI system is suitable for its intended use.

The level of explainability required depends on the system’s function, complexity, and potential impact on GxP decisions.

How to Improve AI Transparency

1. Document the model and its intended use

Validation documentation should describe the model’s purpose, intended users, relevant limitations, assumptions, and operating conditions. Where appropriate, organizations should also document the model’s architecture and key configuration details.

2. Establish explainability requirements

Companies should determine what information users need to understand and evaluate model outputs. For high-impact applications, this may include explanations of important contributing factors, known limitations, and conditions in which the model may perform poorly.

3. Implement human oversight

Qualified personnel should be able to review relevant outputs, identify questionable recommendations, and escalate concerns. Responsibilities for accepting, rejecting, or overriding AI recommendations should be clearly defined.

4. Maintain traceable records

Organizations should retain appropriate records of inputs, outputs, model versions, reviews, and decisions. These records support investigations and help demonstrate that the system operates under controlled conditions.

Challenge 4: Data Dependency and Data Integrity

AI models depend heavily on the quality, relevance, and representativeness of their data. Incomplete, inaccurate, outdated, or biased training data can reduce model performance and lead to unreliable results.

For pharmaceutical companies, data quality is particularly important when AI systems interact with laboratory records, manufacturing data, quality events, or regulated documentation.

Poor data governance can also make it difficult to demonstrate where information originated, whether it was modified, and how it was used by the system.

How to Address Data-Related Challenges

1. Validate training and input data

Organizations should define data quality requirements and evaluate whether datasets are appropriate for the intended application. Relevant checks may include completeness, accuracy, consistency, representativeness, and suitability.

2. Establish data governance procedures

Documented governance procedures should define data ownership, access permissions, review responsibilities, retention requirements, and processes for correcting identified errors.

3. Maintain data provenance

Companies should preserve appropriate information about data sources, transformations, preparation methods, and subsequent use. Traceability supports investigations and helps demonstrate how the model’s results were produced.

4. Apply data integrity controls

Access controls, audit trails, backup procedures, and other appropriate safeguards should be evaluated according to the system’s risks and applicable requirements.

5. Monitor data and model performance

Changes in source data or operating conditions may affect model reliability. Organizations should establish monitoring and investigation procedures for significant performance changes or suspected data integrity issues.

Challenge 5: Regulatory Uncertainty and Evolving Expectations

AI technology is developing rapidly, and regulatory expectations may vary according to the application, jurisdiction, and potential impact on regulated activities.

Pharmaceutical companies must determine how applicable requirements and established GxP principles apply to their AI-enabled systems. They should not assume that using a new technology removes the need for appropriate validation, documentation, risk management, or oversight.

Instead, organizations should adopt a risk-based approach that considers the system’s intended use and its potential effect on product quality, patient safety, and data integrity.

How to Address Regulatory Uncertainty

1. Monitor relevant regulatory developments

Companies should review applicable guidance and regulatory updates from authorities such as the FDA, EMA, Health Canada, and MHRA, where relevant to their operations.

2. Apply risk-based validation

Validation activities should be proportionate to the system’s intended use and associated risks. Systems that directly influence critical GxP decisions may require more extensive controls and evidence than lower-risk administrative applications.

3. Maintain complete documentation

Organizations should document requirements, risk assessments, testing, approvals, changes, deviations, and ongoing monitoring activities as appropriate.

4. Review supplier and third-party controls

When an AI solution is supplied by an external vendor, companies should evaluate the vendor’s documentation, security controls, change notification practices, and ability to support validation activities.

5. Seek qualified compliance guidance

Specialist support can help organizations identify gaps, clarify validation responsibilities, and develop an appropriate compliance strategy for their AI-enabled systems.

How GxP Cellators Helps Address AI and CSV Validation Challenges

GxP Cellators supports regulated organizations with GxP auditing and compliance-related services. Companies evaluating AI-enabled computerized systems may benefit from a structured review of their validation approach, documentation, data controls, and governance processes.

The scope of any engagement should be tailored to the system, intended use, applicable requirements, and risks identified.

AI and CSV Audit Support Services

GxP Cellators can support relevant review activities, including:

• AI CSV validation strategy reviews.
• Computerized system validation documentation reviews.
• AI model validation audits.
• Training data quality audits.
• Data integrity audits.
• Human oversight process reviews.
• Regulatory compliance reviews.
• Mock inspection support.
• Corrective and Preventive Action (CAPA) verification and follow-up.

Why Choose GxP Cellators?

Risk-based approach: Reviews can be tailored to the system’s intended use and potential GxP impact.

Practical recommendations: Audit findings can help organizations identify weaknesses and prioritize corrective actions.

Regulatory awareness: Applicable expectations from relevant authorities can be considered within the agreed audit scope.

Documentation focus: Reviews can assess whether validation records, change control documentation, and supporting evidence are appropriate for the intended use.

Confidentiality: Appropriate confidentiality arrangements are important when reviewing proprietary systems, sensitive records, and business information.

Organizations should confirm the scope, deliverables, and applicable regulatory coverage with GxP Cellators before engaging its services.

Best Practices for Validating AI-Enabled GxP Systems

Although each AI application requires an individual assessment, several practices can help pharmaceutical companies build a more effective validation strategy.

1. Define the intended use: Clearly document what the AI system does, who uses it, and how its outputs influence regulated activities.
2. Conduct a risk assessment: Identify possible effects on product quality, patient safety, data integrity, and regulatory compliance.
3. Establish measurable requirements: Define performance expectations and acceptance criteria before testing begins.
4. Evaluate data quality: Verify that the data used for training, testing, and operation is suitable for the intended purpose.
5. Maintain lifecycle documentation: Record validation activities, approvals, model versions, changes, and relevant investigations.
6. Control system changes: Use documented procedures to assess updates and determine whether additional testing is needed.
7. Provide appropriate oversight: Ensure that qualified personnel understand the system’s limitations and their responsibilities.
8. Monitor performance: Establish procedures for detecting unexpected results, investigating issues, and implementing corrective actions.

These practices help organizations integrate AI into regulated workflows without overlooking established CSV and GxP compliance principles.

Frequently Asked Questions

1. What are the key validation challenges for AI and CSV?

The main challenges include non-deterministic outputs, continuous learning, limited model transparency, data dependency, and evolving regulatory expectations. Organizations should address these through risk-based validation, documented change control, data governance, and ongoing performance monitoring.

2. How can non-deterministic AI outputs be validated?

Companies can define acceptance criteria that account for reasonable output variability, conduct repeated testing, evaluate challenging scenarios, and monitor performance. Where outputs influence critical GxP decisions, appropriate human review should also be established.

3. How can continuous learning be managed in AI systems?

Organizations should establish formal change control, maintain model version records, define revalidation triggers, and monitor performance after relevant changes. The approach should reflect whether the system learns during operation or receives periodic updates.

4. Why is data integrity important for AI validation in pharmaceutical companies?

AI systems rely on the quality and traceability of their data. Poor-quality or unreliable information can affect model performance and undermine confidence in its outputs. Appropriate data governance, access controls, audit trails, and provenance records help manage these risks.

5. How does GxP Cellators help address AI and CSV challenges?

GxP Cellators provides GxP auditing and compliance support that may include AI CSV strategy reviews, validation documentation reviews, model validation audits, data quality assessments, data integrity audits, and mock inspection support, depending on the agreed scope.

6. How can pharmaceutical companies prepare for AI-related regulatory inspections?

Companies should maintain clear documentation of intended use, risk assessments, validation testing, data governance, model changes, performance monitoring, and human oversight. They should also ensure that relevant personnel can explain the system’s role and limitations.

7. Where can I contact GxP Cellators for AI CSV validation support?

You can contact GxP Cellators through its official contact page to discuss your organization’s AI, CSV auditing, and GxP compliance requirements.

Conclusion

AI can offer significant benefits to pharmaceutical companies, but its integration into regulated computerized systems requires careful planning and ongoing oversight. Non-deterministic outputs, model changes, limited transparency, data quality issues, and evolving regulatory expectations can all affect validation activities.

By applying risk-based validation, maintaining reliable documentation, establishing appropriate change control, and monitoring system performance, organizations can better manage these challenges.

GxP Cellators can support relevant auditing and compliance review activities to help organizations identify potential gaps and strengthen their AI and CSV validation approach.

Need support with AI and CSV validation challenges? Visit the GxP Cellators to discuss your requirements.